First copies of Gilead’s Covid-19 drug to start selling in Bangladesh

Bangladesh’s Beximco Pharmaceuticals Ltd. said it has become the world’s first company to start selling the generic version of Gilead Sciences Inc.’s antiviral drug on mounting urgency to treat the infection caused by the deadly coronavirus across the developing world.
The Dhaka-based Beximco, which counts Norges Bank as one of its investors, will sell remdesivir for about 6,000 takas ($71) a vial to private clinics but will give it free to state-run hospitals treating Covid-19 patients, Rabbur Reza, chief operating officer at the company, said in an interview. A critically ill Covid-19 patient will need at least six vials, he said.
Bangladesh can produce generic versions of patented drugs under World Trade Organization provisions that grant least developed countries a waiver from seeking licenses. Remdesivir was cleared by U.S. drug regulator for emergency use in Covid-19 patients, becoming the first medication backed by early clinical data to be made available to fight the novel pathogen.
“We’re also receiving queries from other countries,” Reza said. “The drug will not be supplied through traditional distribution channels. If some governments need our drug, we’ll export it.”
Bangladesh had more than 26,000 infected cases as of Wednesday, while the disease had killed 386, according to data from Johns Hopkins University
The United Nations-backed Medicines Patent Pool, which is helping Gilead find partners, contacted Beximco asking if it was interested in the voluntary licensing for remdesivir, said Reza. Beximco is waiting to hear back, he said.
A Gilead representative didn’t respond to an email seeking comment.
Gilead has since licensed five companies including Cipla Ltd. and Mylan NV in India and Ferozsons Laboratories Ltd. in Pakistan to make generic versions of the drug and sell in 127 countries.
Norway’s Norges Bank, the world’s biggest sovereign fund, controls 3% of Beximco, according to data compiled by Bloomberg. Beximco will sell the drug under the brand name bemsivir, according to a statement from the company.
Author Profile
Monika Walker is a senior journalist specializing in regional and international politics, offering in-depth analysis on governance, diplomacy, and key global developments. With a degree in International Journalism, she is dedicated to amplifying underrepresented voices through factual reporting. She also covers world news across every genre, providing readers with balanced and timely insights that connect the Caribbean to global conversations.
Latest
- Saint Lucia: K-9 Dog Tyson laid to rest with Military honors...
-
Saint Lucia records 48th homicide of 2025 as Gros Islet Shoo... -
Israel-Qatar Tensions Escalate: Doha hosts emergency Arab-Is... -
Trinidad: Newborn baby dies 2 days after birth, police launc... -
Arima North Secondary fight caught on camera, parents raise...